Tag Archives: Kyinsu

October CHMP Agenda Highlights; Pfizer Initiates Q3M Berobenatide Study; Novo Licenses New Drug Discovery Platform; Fractyl Shares 6-Month Revita Procedure Results; FDA Reaffirms Reta’s Classificaiton as a Drug; MiniMed Appoints Board; Sequel twiist AID Insulin-Treated T2DM FDA Clearance

A series of cardiometabolic-related news items has been observed from EMA, Pfizer, Novo/Ablexis, Fractyl Health, FDA/Lilly, MiniMed, and Sequel Med Tech. Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Insulet Omnipod Discover Launch; October CHMP Agenda

Two cardiometabolic-related news items have been observed: Insulet launched its Omnipod Discover platform in the US (view press release), and the CHMP agenda for this month’s meeting (October 12-15) has been released (view agenda). Below, FENIX provides highlights and insights for the respective news items.

This content is for Read Less members only.
Already a member? Log in here

Positive Pants Part 2: Novo 2026 Capital Markets Day Highlights and Analysis

Part 2 of FENIX’s 2026 Novo CMD coverage recaps commentary on US commercial operations, global manufacturing & supply, and international operations. Each of these three components is viewed as integral to Novo’s future success while it attempts to maintain (and grow) its place in the CVRM market ahead of the onslaught of obesity competitors looking to eat its lunch.

This content is for Read Less members only.
Already a member? Log in here

New Foundayo DTC Ad; Roche Shares New INN for CT-388; April CHMP Agenda

Three cardiometabolic-related news items have been observed: Lilly aired a new Foundayo DTC ad on social media platforms (view Reddit post); Roche’s CT-388 has been given the INN of enicepatide, which is reflected in two Ph2 studies (view CT.gov record; view CT.gov record); and the CHMP agenda for this month’s meeting (April 20-23) has been released (view here). Below, FENIX provides highlights and insights on the respective news items.

This content is for Read Less members only.
Already a member? Log in here

EASD 2025 Key Press Releases (September 19) 

On the final day of EASD 2025, four key news items were observed from Novo Nordisk, Skye Bioscience, Ionis/Sobi, and Innovent. Below, FENIX provides context and analysis for the announcements.

This content is for Read Less members only.
Already a member? Log in here